Several epidemiological and experimental studies suggested that n-3 PUFA could exert favorable effects on the atherotrombotic cardiovascular disease including arrhythmias. The GISSI team investigated whether n-3 PUFA could improve morbidity and mortality in a large population of patients with symptomatic heart failure of any cause.